U.S. FDA says some data testing Novartis' $2 million gene therapy was manipulated
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/13/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Former emir of Qatar, Sheikh Hamad bin Khalifa Al Thani, dies at 74
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- Apple sues OpenAI, two former employees for trade secrets theft
PTC Therapeutics (PTCT) Misses Q2 EPS by 17c, Revenues Beat
August 6, 2019 5:25 PM EDTPTC Therapeutics (NASDAQ: PTCT) reported Q2 EPS of ($0.75), $0.17 worse than the analyst estimate of ($0.58). Revenue for the quarter came in at $85.5 million versus the consensus estimate of $78.64 million.
Second quarter 2019 financial highlights:
Total revenues were $85.5 million for the second quarter of 2019, compared to $68.7 million for the second quarter of 2018.Translarna net product revenues were $57.8 million for the second quarter of 2019, compared to $47.8 million for the second quarter of 2018. These results reflect the expanded commercialization of Translarna.Emflaza net product revenues were $27.6 million for the second quarter of 2019, compared to... More